Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

Kazuhiro Kamata; Kazuaki Jindai; Nao Ichihara; Hiroki Saito; Hideaki Kato; Hiroyuki Kunishima; Ayumi Shintani; Osamu Nishida; Shigeki Fujitani

doi:10.1186/s40560-021-00547-7

Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

Kazuhiro Kamata
, Kazuaki Jindai
, Nao Ichihara
, Hiroki Saito
, Hideaki Kato
, Hiroyuki Kunishima
, Ayumi Shintani
, Osamu Nishida
, Shigeki Fujitani

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Abstract

REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.

Original language	English
Article number	34
Journal	Journal of Intensive Care
Volume	9
Issue number	1
DOIs	https://doi.org/10.1186/s40560-021-00547-7
Publication status	Published - 12-2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Critical Care and Intensive Care Medicine

Access to Document

10.1186/s40560-021-00547-7

Cite this

@article{71abb33c41214db0baf05fb9775f1222,

title = "Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan",

abstract = "REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.",

author = "Kazuhiro Kamata and Kazuaki Jindai and Nao Ichihara and Hiroki Saito and Hideaki Kato and Hiroyuki Kunishima and Ayumi Shintani and Osamu Nishida and Shigeki Fujitani",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s40560-021-00547-7",

language = "English",

volume = "9",

journal = "Journal of Intensive Care",

issn = "2052-0492",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

AU - Kamata, Kazuhiro

AU - Jindai, Kazuaki

AU - Ichihara, Nao

AU - Saito, Hiroki

AU - Kato, Hideaki

AU - Kunishima, Hiroyuki

AU - Shintani, Ayumi

AU - Nishida, Osamu

AU - Fujitani, Shigeki

PY - 2021/12

Y1 - 2021/12

N2 - REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.

AB - REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.

UR - https://www.scopus.com/pages/publications/85104402711

UR - https://www.scopus.com/pages/publications/85104402711#tab=citedBy

U2 - 10.1186/s40560-021-00547-7

DO - 10.1186/s40560-021-00547-7

M3 - Letter

AN - SCOPUS:85104402711

SN - 2052-0492

VL - 9

JO - Journal of Intensive Care

JF - Journal of Intensive Care

IS - 1

M1 - 34

ER -

Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this